25.06.2012 • NewsHovionesales and profitsQ1 2012

Hovione's Sales Grow 24%

Hovione announced that the consolidated sales for the fiscal year ended March 2012 amounted to $180 million, the sixth consecutive year of sales growth, representing a growth of 24% in relation to last year.

In addition to the financial results, which reflect the quality of the Team's performance, overall 2011 represented a year of great achievements, namely:

Hovione stood behind 3 NDA approvals, these were all major NMEs - and in two cases the approvals were full QbD filings in which Hovione was central to the design and data generation.

All Hovione plants underwent several successful GMP inspections by one or more of the major Medicines' Agencies - a reflection of the large flow of filings and the high standards of compliance.

 

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.